Evotec AG has entered into an agreement with AstraZeneca Plc to explore compounds and targets for the treatment of chronic kidney disease. The agreement involves an undisclosed upfront payment as well as performance-related milestone payments. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
